secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0000950170-24-018431
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio's acoramidis NDA accepted by FDA with PDUFA Nov 29, 2024; secured $1.25B capital; Q4 net loss $168M
--------------------------------------------------------------------------------

- Acoramidis NDA accepted by FDA; PDUFA Nov 29, 2024. Phase 3 met primary endpoint (Win Ratio 1.8, p<0.0001).
- Secured up to $1.25B from Blue Owl and CPP Investments: $500M upfront for 5% royalty on acoramidis net sales and $450M credit facility.
- Q4 2023 net loss attributable to common stockholders $168.1M ($0.96 EPS) vs $137.6M ($0.92 EPS) YoY; revenue $1.7M down from $1.9M.
- Cash and cash equivalents $392.6M as of Dec 31, 2023. Full year net loss $643.2M; operating cash used $527.7M.
- Partnership with Kyowa Kirin for infigratinib in Japan: $100M upfront, royalties up to high-twenties percent, milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017024018431/0000950170-24-018431-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017024018431/bbio-20240222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-018431

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer